{"nctId":"NCT01333111","briefTitle":"Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients","startDateStruct":{"date":"2011-04-27","type":"ACTUAL"},"conditions":["Congenital Bleeding Disorder","Haemophilia B"],"count":74,"armGroups":[{"label":"Prophylaxis, high dose (trial duration 52 weeks)","type":"EXPERIMENTAL","interventionNames":["Drug: nonacog beta pegol"]},{"label":"Prophylaxis, low dose (trial duration 52 weeks)","type":"EXPERIMENTAL","interventionNames":["Drug: nonacog beta pegol"]},{"label":"On-demand (trial duration 28 weeks)","type":"EXPERIMENTAL","interventionNames":["Drug: nonacog beta pegol"]}],"interventions":[{"name":"nonacog beta pegol","otherNames":["NNC-0156-0000-0009"]},{"name":"nonacog beta pegol","otherNames":["NNC-0156-0000-0009"]},{"name":"nonacog beta pegol","otherNames":["NNC-0156-0000-0009"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male patients with moderately severe or severe congenital haemophilia B with a factor IX activity of 2% or below according to medical records\n* History of at least 150 exposure days to other factor IX products\n* Patients currently treated on-demand with at least 6 bleeding episodes during the last 12 months or at least 3 bleeding episodes during the last 6 months, or patients currently on prophylaxis\n\nExclusion Criteria:\n\n* Known history of factor IX inhibitors based on existing medical records, laboratory report reviews and patient and legally acceptable representative (LAR) interviews\n* HIV (Human immunodeficiency virus) positive, with a viral load equal to or above 400,000 copies/mL and/or CD4+ lymphocyte count equal to or below 200/microL\n* Congenital or acquired coagulation disorders other than haemophilia B\n* Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)\n* Immune modulating or chemotherapeutic medication","healthyVolunteers":false,"sex":"MALE","minimumAge":"13 Years","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Inhibitory Antibodies Against Factor IX Defined as Titre Equal to or Above 0.6 BU (Bethesda Units)","description":"Inhibitors were analysed with either the Nijmegen modified factor IX Bethesda assay or a heat/cold Nijmegen modified factor IX Bethesda assay. Number of subjects who developed inhibitory antibodies against factor IX are reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Inhibitory Antibodies Against Factor IX Defined as Titre Equal to or Above 0.6 BU (Bethesda Units)","description":"Inhibitors were analysed with either the Nijmegen modified factor IX Bethesda assay or a heat/cold Nijmegen modified factor IX Bethesda assay. Number of subjects who developed inhibitory antibodies against factor IX are reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Haemostatic Effect of NNC-0156-0000-0009 When Used for Prophylaxis of Bleeding Episodes, Assessed as Success/Failure Based on a Four-point Scale for Haemostatic Response","description":"Haemostatic response after treatment of a bleed with nonacog beta pegol was evaluated on a 4 point scale as excellent, good, moderate or poor. A success rate was calculated based on counting good or excellent as successes and poor and moderate as failures.\n\n* Excellent - abrupt pain relief and/or clear improvement in objective signs of bleeding within 8 hours after a single injection\n* Good - noticeable pain relief and/or improvement in signs of bleeding within 8 hours after a single injection\n* Moderate - probable or slight beneficial effect within the first 8 hours after the first injection but requiring more than one injection within 8 hours\n* Poor - no improvement, or worsening of symptoms within 8 hours after two injections.\n\nThe success rate and 95% confidence interval (CI) are reported here.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.9","spread":null},{"groupId":"OG001","value":"97.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Haemostatic Effect of NNC-0156-0000-0009 When Used for Treatment of Bleeding Episodes, Assessed as Success/Failure Based on a Four-point Scale for Haemostatic Response","description":"Haemostatic response after treatment of a bleed with nonacog beta pegol was evaluated on a 4 point scale as excellent, good, moderate or poor. A success rate was calculated based on counting good or excellent as successes and poor and moderate as failures.\n\n* Excellent - abrupt pain relief and/or clear improvement in objective signs of bleeding within 8 hours after a single injection\n* Good - noticeable pain relief and/or improvement in signs of bleeding within 8 hours after a single injection\n* Moderate - probable or slight beneficial effect within the first 8 hours after the first injection but requiring more than one injection within 8 hours\n* Poor - no improvement, or worsening of symptoms within 8 hours after two injections.\n\nThe success rate and 95% confidence interval (CI) are reported here.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Bleeding Episodes Per Patient During Routine Prophylaxis","description":"The number of bleeding episodes per patient during routine prophylaxis was assessed using the individual annualised bleeding rates (spontaneous and traumatic bleeding episodes per patient per year).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":"5.41"},{"groupId":"OG001","value":"1.04","spread":"7.41"}]}]}]},{"type":"SECONDARY","title":"Factor IX Trough Levels","description":"The mean pre-dose factor IX levels was measured with the one-stage clotting assay during the trial. Lowest factor IX activity recorded during single-dose and steady state, immediately before next dose was given. The analysis was based on a mixed model on the log-transformed plasma factor IX activity with subject as a random effect. The estimated mean factor IX trough level was presented back-transformed to the natural scale.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.085","spread":null},{"groupId":"OG001","value":"0.273","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Adverse Events (AEs)","description":"The incidence of adverse events were summarised by the rate of AEs (number of AEs per patient years of exposure \\[PYE\\]). Number of adverse events per PYE is number of adverse events /total time in trial. All adverse events reported are treatment emergent (any adverse events which occurred after trial product administration).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.62","spread":null},{"groupId":"OG001","value":"3.83","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Adverse Events (AEs)","description":"The incidence of adverse events were summarised by the rate of AEs (number of AEs per PYE). Number of adverse events per PYE is number of adverse events /total time in trial. All adverse events reported are treatment emergent (any adverse events which occurred after trial product administration).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Serious Adverse Events (SAEs)","description":"SAE was defined as an AE that resulted in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect. The incidence of SAEs were summarised by the rate of SAEs (number of SAEs per PYE). Number of SAEs per PYE is number of SAEs/total time in trial. All SAEs reported are treatment emergent (any serious adverse events which occurred after trial product administration).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null},{"groupId":"OG001","value":"0.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Serious Adverse Events (SAEs)","description":"SAE was defined as an AE that resulted in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect. The incidence of SAEs were summarised by the rate of SAEs (number of SAEs per PYE). Number of SAEs per PYE is number of SAEs/total time in trial. All SAEs reported are treatment emergent (any serious adverse events which occurred after trial product administration).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Host Cell Proteins (HCP) Antibodies","description":"Subjects who were positive for anti-Host Cell Protein (HCP) antibodies.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Host Cell Proteins (HCP) Antibodies","description":"Subjects who were positive for anti-HCP antibodies.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":30},"commonTop":["Nasopharyngitis","Influenza","Upper respiratory tract infection","Headache","Fatigue"]}}}